
ZBH Stock Forecast & Price Target
ZBH Analyst Ratings
Bulls say
Zimmer Biomet Holdings is well-positioned in the orthopedic market, with a leading share in the US, Europe, and Japan. The company's recent acquisitions have strengthened its product portfolio, particularly in large joints and extremities. Although the first quarter of 2026 had some issues, the company's strategic initiatives and product launches are expected to contribute positively to its longer-term fundamentals. While not without risks, optimistic analysts believe that Zimmer Biomet has the potential for faster revenue and earnings growth, which could lead to a higher valuation for the company.
Bears say
Zimmer Biomet Holdings is facing challenges with its sales force transformation, causing disruptions in the market and contributing to underperformance in the US knees segment. This transition is expected to continue until 2027 and may lead to short-term executional hurdles. Although the company has a strong market share and a diverse product portfolio, these factors may outweigh its long-term potential for financial returns and multiple expansion, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Zimmer Biomet Hlds and is not a guaranteed prediction by Public.com or investment advice.
ZBH Analyst Forecast & Price Prediction
Start investing in ZBH
Order type
Buy in
Order amount
Est. shares
0 shares